Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book, 1st Edition
From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area.
From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area.
特長
- Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care.
- Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care.
- Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon.
- Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.
著者情報
| ISBN Number | 9780323755979 |
|---|---|
| Description Author List | Edited by Daniel W. Lee and Nirali N. Shah, Lasker Clinical Research Scholar, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, United States |
| Copyright Year | 2020 |
| Edition Number | 1 |
| Format | E-Book |
| Trim | 191w x 235h (7.50" x 9.25") |
| Imprint | Elsevier |
| Page Count | 230 |
| Publication Date | 30 Nov 2019 |
| Stock Status | IN STOCK |
Introduction
1. When to Refer a Patient for CAR-T Cell Therapy
2. Optimizing the Apheresis Product
3. CAR T Cells: Cell Processing Laboratory Considerations
4. Peri-CAR-T Cell Management
5. Management of Cytokine Release Syndrome
6. Special Considerations for ICU Management of Patients Receiving CAR Therapy
7. Neurotoxicities After CAR-T Cell Immunotherapy
8. Hematologic and Non-CRS Toxicities
9. Response Assessment and PosteCAR-T Cell Therapy Management
10. Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR-T Cell Therapy
11. Promising Chimeric Antigen Receptors for Non-B Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas
12. CAR T Cell Therapy for CNS Malignancies
13. CAR 2.0: The Next Generation of Synthetic ReceptoreBased Cellular Therapy for Cancer
